Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Return on Sales (2016 - 2025)

Historic Return on Sales for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to 1.62%.

  • Marker Therapeutics' Return on Sales fell 4200.0% to 1.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.47%, marking a year-over-year increase of 95900.0%. This contributed to the annual value of 53.66% for FY2024, which is 554100.0% down from last year.
  • As of Q3 2025, Marker Therapeutics' Return on Sales stood at 1.62%, which was down 4200.0% from 4.8% recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Return on Sales registered a high of 8.67% during Q2 2023, and its lowest value of 478.06% during Q2 2021.
  • Over the past 5 years, Marker Therapeutics' median Return on Sales value was 1.41% (recorded in 2024), while the average stood at 44.95%.
  • Per our database at Business Quant, Marker Therapeutics' Return on Sales crashed by -4644700bps in 2021 and then skyrocketed by 4729800bps in 2022.
  • Quarter analysis of 5 years shows Marker Therapeutics' Return on Sales stood at 256.13% in 2021, then soared by 100bps to 1.07% in 2022, then skyrocketed by 94bps to 0.06% in 2023, then surged by 1636bps to 0.92% in 2024, then plummeted by -277bps to 1.62% in 2025.
  • Its Return on Sales was 1.62% in Q3 2025, compared to 4.8% in Q2 2025 and 12.74% in Q1 2025.